Ostarine (MK-2866) Liquid

Buy Ostarine (MK-2866) Liquid Online

Ostarine, also known as MK-2866 or enobosarm, is a selective androgen receptor modulator developed to investigate tissue-selective anabolic activity. It has progressed considerably further in human research than many other SARMs.

Product Information

Enobosarm selectively activates androgen receptors and has been investigated in clinical trials involving muscle wasting, lean body mass, and physical function. The liquid format does not alter the pharmacology of the active compound. Ostarine is also known as enobosarm, MK-2866, GTx-024, and S-22.

How It Works

Ostarine binds androgen receptors and activates anabolic signaling in tissues such as skeletal muscle and bone. Its development focused on producing anabolic effects while limiting some androgenic activity associated with traditional anabolic steroids.

POTENTIAL BENEFITS

1. Lean-Mass Research

Controlled clinical trials have demonstrated increases in lean body mass with enobosarm, making Ostarine one of the most extensively studied SARMs in this area.

2. Muscle-Wasting Research

Clinical research has investigated enobosarm in conditions associated with muscle loss, including cancer-related wasting, providing useful data on anabolic effects.

3. Physical-Function Research

Studies have examined whether increases in lean body mass translate into measurable improvements in physical performance and function.

4. Selective Anabolic Research

Ostarine is an important research model for understanding whether androgen-receptor activation can be directed toward muscle and bone while reducing unwanted effects in other androgen-sensitive tissues.

Dosage

Clinical trials have evaluated 1 mg and 3 mg once daily in cancer-related muscle wasting, while a separate phase II study in older adults evaluated 3 mg/day. These are clinical-trial exposures, not a general recommendation for unsupervised use.

Side Effects

Potential concerns include suppression of endogenous hormone production, lipid changes, liver effects, and other androgen-related adverse effects. Long-term safety outside controlled clinical research remains incompletely established.

References

1. Dalton et al. — GTx-024 (enobosarm) in healthy elderly men and postmenopausal women. PMID: 22031847
2. Dobs et al. — Enobosarm in patients with cancer-related muscle wasting. PMID: 23499390
3. PubMed — Enobosarm/Ostarine clinical research

Note: BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

Please click here to see how purchases actually work on this site.